Shubham Singh

The medtech giant closed out fiscal 2026 with double-digit cardiovascular gains and a string of acquisitions, while bracing for $250m in tariff headwinds.

The former Medtronic Diabetes unit posted strong international numbers and a pipeline of new products, while US growth lagged on a self-inflicted timing issue tied to an early regulatory win.

Dexcom's deal for Nutrisense comes as glucose monitoring companies race to become full metabolic-health ecosystems — a contest the company is betting will be decided by coaching and nutrition support, not sensor accuracy alone.

A 26-week randomized trial in non-insulin type 2 patients has handed Dexcom its most consequential clinical result yet — Level A evidence that continuous glucose monitoring meaningfully outperforms standard care in a population that guidelines have largely left behind.

CEO Jake Leach maps out the path from diabetes device maker to full-spectrum metabolic health platform — with new silicon, hospital ambitions, and a dietitian coaching business now in the fold.

Medtech's latest earnings season was a deal briefing. Balance sheets are ready, valuations are moving, and the industry's biggest names are closing transactions — not just signaling intent.

Get the latest ElevenLabs promo code 2026 and save up to 50% off on the Creator plan plus 17% off annual billing.

Check 13 best SaaS content marketing agencies in 2026 ranked by SEO performance, revenue impact, and proven SaaS growth results.

Ambient AI scribes are lifting physician revenue, but the same tools are intensifying coding patterns commercial payers are starting to push back on. Provider consolidation is amplifying the pressure.

ResMed has spent decades treating obstructive sleep apnea. Its $340m acquisition of Noctrix Health signals something different — a deliberate move into restless legs syndrome (RLS), the third most prevalent sleep disorder in the US and one Resmed's core technology was never designed to address.